Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
description
Transcript of Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 1: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/1.jpg)
<br /><br />E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 2: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/2.jpg)
A Quick Review of the History of Hormone Sensitive Metastatic Prostate Cancer
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 3: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/3.jpg)
Early Chemo+ADT: A debate in one slide – a need for randomized phase 3 trial
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 4: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/4.jpg)
The CHAARTED Hypothesis
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 5: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/5.jpg)
E3805 – CHAARTED Treatment
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 6: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/6.jpg)
Key Eligibility Criteria
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 7: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/7.jpg)
Study Endpoints
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 8: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/8.jpg)
Statistical Design: History of CHAARTED<br />Intent to treat analysis, 80% power 1-sided alpha=2.5% to detect 33% improvement in median OS (with all versions)
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 9: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/9.jpg)
Results:
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 10: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/10.jpg)
Patient characteristics
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 11: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/11.jpg)
Patient characteristics
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 12: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/12.jpg)
Patient characteristics
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 13: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/13.jpg)
Primary endpoint: Overall survival
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 14: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/14.jpg)
Causes of Death
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 15: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/15.jpg)
OS by extent of metastatic disease at start of ADT
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 16: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/16.jpg)
ADT + Docetaxel benefited all subgroups
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 17: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/17.jpg)
Secondary Endpoints
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 18: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/18.jpg)
Therapy beyond progression
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 19: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/19.jpg)
Chemotherapy Doses Given
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 20: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/20.jpg)
Non-Hematologic Toxicity (%)
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 21: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/21.jpg)
Hematologic Toxicity (%)
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 22: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/22.jpg)
Conclusion
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 23: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/23.jpg)
Clinical interpretation
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
![Page 24: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting](https://reader030.fdocuments.in/reader030/viewer/2022012922/5681658e550346895dd85ad1/html5/thumbnails/24.jpg)
Designed and conducted by:
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting